Zoetis Q1 Goes Flat as US Companion Animal Slips 11%

Q1 2026 revenue at Zoetis (NYSE: ZTS), the world's largest animal health company, came in at $2.3 billion, up 3% reported but flat on an organic operational basis, with US companion animal sales down 11% on softer demand and rising competitive pressure across the dermatology and parasiticide franchises. Analysts called it a significant negative inflection point for the US business. Companion animal therapeutics is now openly contested, and the assumption that Zoetis dominates the category by default no longer holds.

Zoetis Q1 revenue flat, US companion animal down 11%

Zoetis (NYSE: ZTS) reported Q1 2026 revenue of $2.3 billion on May 7, an increase of 3% as reported and flat on an organic operational basis. Adjusted net income was $646 million, or $1.53 per diluted share — up 9% reported and 7% on an organic operational basis.

The US companion animal segment fell 11%. Management cited softer end-market demand, an "increasingly competitive landscape" pressuring the dermatology franchise and Simparica Trio, persistent macroeconomic price sensitivity, generic competition on Convenia and Cerenia, and lower sales of Librela, the company's monoclonal antibody for canine osteoarthritis pain.

International companion animal grew 15% reported and 7% organic operational, led by parasiticides, diagnostics, vaccines, and price timing.

Zoetis updated full-year 2026 guidance to revenue of $9.68 to $9.96 billion and adjusted diluted EPS of $6.85 to $7.00, implying low- to mid-single-digit organic operational growth.

Analysts framed the print as a "significant negative inflection point" for the US business. Shares fell on the release.

Why the companion animal share war just got real

This Q1 print marks a competitive inflection. Zoetis isn't reporting a cyclical air pocket. It's reporting share loss to a competitor that, eighteen months ago, was widely written off.

1. Simparica Trio is now a contested category. Zoetis explicitly named Simparica Trio as a source of US weakness. In the same week, Elanco's Q1 commentary cited "accelerating market share gains" from Credelio Quattro, the all-in-one canine parasiticide that bundles tapeworm coverage with the standard flea, tick, and heartworm package. For DTC pet brands modeling parasiticide attach rates and pet insurers modeling Rx cost trends, the assumption that one molecule dominates is wrong.

2. The dermatology franchise faces its first credible competitor at scale. Apoquel powered Zoetis dermatology for a decade. Elanco's Zenrelia, a daily JAK inhibitor for canine pruritus, just hit trailing-four-quarter blockbuster status — meaning a billion-dollar competitor on the shelf in less than two years from launch. Vets are willing to switch. The "gold standard" framing that worked through 2024 doesn't sell the same way in 2026.

3. Librela is no longer a one-modality category. Zoetis named lower Librela sales as a Q1 contributor. The launch was the most-watched companion animal drug rollout of the decade, and most pet-pharma TAM models assumed it would compound. The same week, Gallant moved its IV-delivered stem cell therapy for canine osteoarthritis onto an expanded FDA conditional approval pathway. The osteoarthritis category now has real modality competition: NSAIDs, Librela, IV cell therapy in trials, and pending generic mAb pressure.

4. The US-international split is too wide to blame on macro. US fell 11%; international grew 7% organic. Macro alone doesn't produce an 1,800-basis-point spread inside a single quarter. The split points to channel mix, pricing power, and product cycle running differently inside the US vet practice — exactly the customer most pet-tech and DTC operators built their go-to-market around.

5. Compounding is the lost assumption. The valuation case for Zoetis since its 2013 spin from Pfizer has rested on durable double-digit organic compounding inside companion animal. One flat-organic quarter doesn't break that case. But it puts the case on probation. Operators downstream — vet groups, distributors, specialty Rx, subscription pet brands — should rebuild LTV models with competitor entry as a default, not a tail risk.

How Zoetis defends Simparica Trio and Librela in Q2

Simparica Trio response: Pricing actions, expanded indications, or a new flagship parasiticide announcement. Zoetis has a deep R&D bench. The defense move tells you whether management reads Q1 as cyclical or structural.

Librela US trajectory: Q2 sales as a category check. Watch whether the launch curve has plateaued or is being directly compressed by alternative modalities like Gallant's UMSC pipeline and pending generic mAb pressure.

Net pricing disclosures: Both Zoetis and Elanco have to clarify net price across parasiticides at Q2. The category was protected by branded pricing power for a decade. Live competition will test it.

International pipeline: International companion animal at +7% organic is the bull case for Zoetis. Whether that holds against currency, regional competition, and the same emerging modality pipeline is the question through 2H 2026.

M&A signal: Zoetis has the balance sheet and the strategic rationale to acquire a cell-therapy or oncology biotech to defend the OA category. A strategic acquisition between now and year-end would be the strongest signal that management reads Q1 as structural, not noise.

Source: Zoetis Q1 2026 release via Business Wire